Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Cardiology · Heart Failure with Reduced Ejection Fraction

Standard of Care: The Four Pillars of Heart Failure Treatment

At a Glance

For eligible people with systolic heart failure, the four core medication groups are an ARNI, an evidence-based beta-blocker, an MRA, and an SGLT2 inhibitor. Doctors often start low doses promptly and monitor kidney function, potassium, blood pressure, and heart rate.

While your heart failure diagnosis is serious, the treatment for Heart Failure with reduced Ejection Fraction (HFrEF) has entered a new era. We now have a standard approach to treatment known as Guideline-Directed Medical Therapy (GDMT).

When these medications are used together in eligible patients, they don’t just treat symptoms—they fundamentally change the biology of your heart, helping it stay stronger and helping you live longer [1].

The Four Pillars of GDMT

Modern heart failure care is built on four specific classes of medication. Each works in a different way to shield your heart from the “vicious cycle” of stress and remodeling [1][2].

  1. ARNI (Angiotensin Receptor-Neprilysin Inhibitor): Usually the drug sacubitril/valsartan. This is often preferred over older drugs like ACE inhibitors or ARBs because it provides superior protection against heart failure hospitalizations [3][4]. Safety Note: If you are switching from an older ACE inhibitor (like lisinopril) to an ARNI, you must wait a full 36 hours after your last ACE inhibitor dose before taking the ARNI to prevent a severe allergic swelling called angioedema [4][5].
  2. Evidence-Based Beta-Blockers: Specifically carvedilol, bisoprolol, or metoprolol succinate (extended-release). These slow the heart rate and block the toxic effects of adrenaline [1][6]. Do not stop beta-blockers abruptly.
  3. MRA (Mineralocorticoid Receptor Antagonist): Such as spironolactone or eplerenone. These block a hormone that causes scarring in the heart and fluid retention [7][8]. Spironolactone carries a risk of breast tenderness or enlargement (gynecomastia) in some men.
  4. SGLT2 Inhibitor: Drugs like dapagliflozin or empagliflozin. Originally used for diabetes, these are now a core therapy for heart failure because they reduce the risk of heart failure events and cardiovascular complications [9][10].

Why All Four?

The benefits of these drugs are additive. An eligible patient on all four pillars generally has a lower risk of death or hospitalization compared to someone on just one or two [11]. Modeling estimates suggest that for some patients, being on all four therapies could add years to their life compared to older treatment methods [11].

A New Strategy: Rapid Initiation

In the past, doctors would start one drug and wait months to reach a high dose before starting the next. Today, the strategy has shifted to rapid initiation.

Experts now recommend starting all four pillars at low doses as quickly as possible—ideally within 2 to 6 weeks of diagnosis—when safely tolerated [12][13]. This approach is favored because the benefits start within days or weeks, even at low doses [2][14]. However, this sequence is highly individualized. Beta-blockers, for example, are generally started only when you are clinically stable and not severely congested [15]. Once you are safely taking all four, your doctor will slowly “uptitrate” the doses based on your blood pressure and kidney function.

Managing Symptoms: Diuretics

You may also be prescribed a loop diuretic (like furosemide, bumetanide, or torsemide). It is important to know that diuretics are not one of the four pillars. While they are vital for removing extra fluid and helping you breathe better, they do not “fix” the heart’s biology or extend your life in the same way GDMT does [16][17].

Safety and Monitoring

Because three of the four pillars (ARNI, MRA, and SGLT2i) can affect your kidneys and electrolytes, close monitoring is required.

  • Lab Checks: You will need regular blood tests to check your creatinine (a measure of kidney function) and potassium [18][19].
  • The “Kidney Bump”: An early change in creatinine can occur, but it can also reflect dehydration, low blood pressure, or medication interactions. Never ignore significant lab changes, and do not adjust doses yourself [20][21].
  • Potassium Levels: MRAs can raise potassium to dangerous levels. If your potassium goes too high, your doctor may lower the dose or prescribe a “potassium binder” [7][22].
  • SGLT2i Sick-Day Rules: Ask your care team about pausing SGLT2 inhibitors during major illnesses, fasting, or surgery to prevent a rare condition called ketoacidosis. These drugs also carry a risk of genital yeast infections.
  • Blood Pressure and Heart Rate: Monitor for dizziness (hypotension) or excessively slow heart rate (bradycardia) and report them promptly.

Self-advocacy is key: If you are not on all four pillars, ask your care team if there is a specific medical reason why, or if you can begin the process of safely starting them [2].

Common questions in this guide

What are the four pillars of treatment for systolic heart failure?
For eligible people with heart failure with reduced ejection fraction, the four pillars are an ARNI such as sacubitril/valsartan, an evidence-based beta-blocker, an MRA such as spironolactone or eplerenone, and an SGLT2 inhibitor such as dapagliflozin or empagliflozin. They work through different pathways and together can lower the risk of hospitalization and death.
How soon should I start all four heart failure medicines?
When safely tolerated, clinicians often start low doses of all four medication groups within about 2 to 6 weeks of diagnosis. The order and timing depend on blood pressure, fluid congestion, kidney function, potassium, heart rate, and overall stability; doses are increased gradually.
Are water pills part of the four pillars?
Loop diuretics such as furosemide, bumetanide, and torsemide are not one of the four disease-modifying pillars. They remove extra fluid and can improve swelling or breathing, but they do not provide the same long-term heart protection as the four core medication groups.
What blood tests and vital signs need monitoring?
Blood tests usually include creatinine, which helps assess kidney function, and potassium. Your care team may also monitor blood pressure and heart rate for low blood pressure or an unusually slow pulse. A change in creatinine or potassium should be reviewed by a clinician; do not change a dose yourself.
Why do I need to wait before switching from an ACE inhibitor to an ARNI?
A full 36-hour gap after the last ACE inhibitor dose is recommended before starting an ARNI such as sacubitril/valsartan. This lowers the risk of angioedema, a potentially severe swelling reaction.
What should I do if I am not taking all four pillars?
Ask your heart-failure care team whether there is a specific medical reason a medicine has not been started and what the plan is. Some medicines may need to wait until congestion, blood pressure, kidney function, potassium, or other safety issues are stable, but eligible patients should be assessed for all four.
When might I need to pause an SGLT2 inhibitor?
Ask your care team whether you should temporarily pause an SGLT2 inhibitor during a major illness, fasting, or surgery, because a rare condition called ketoacidosis can occur. These medicines can also increase the risk of genital yeast infections, so report concerning symptoms to your care team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I currently on the 'Four Pillars' of heart failure therapy? If not, what is the plan to start them?
  2. 2.What is the target dose for each of my heart medications, and how quickly will we increase them?
  3. 3.What was my latest potassium and creatinine level, and how often will we check these labs as we adjust my doses?
  4. 4.Which of my medications are 'disease-modifying' (protecting my heart) versus 'symptom-modifying' (managing fluid)?
  5. 5.If my blood pressure or kidney labs change slightly, does that mean we must stop the medication, or can we continue at a lower dose?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Guidelines for treating heart failure.

    Kittleson MM

    Trends in cardiovascular medicine 2025; (35(3)):141-150 doi:10.1016/j.tcm.2024.10.002.

    PMID: 39442740
  2. 2

    Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.

    Malgie J, Clephas PRD, Brunner-La Rocca HP, et al.

    Heart failure reviews 2023; (28(5)):1221-1234 doi:10.1007/s10741-023-10325-2.

    PMID: 37311917
  3. 3

    Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.

    Okumura N, Jhund PS, Gong J, et al.

    Circulation. Heart failure 2016; (9(9)).

    PMID: 27618854
  4. 4

    Inpatient Initiation of Sacubitril/Valsartan.

    Chilbert MR, Rogers KC, Ciriello DN, et al.

    The Annals of pharmacotherapy 2021; (55(4)):480-495 doi:10.1177/1060028020947446.

    PMID: 32741197
  5. 5

    Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.

    Rodgers JE

    The American journal of medicine 2017; (130(6)):635-639 doi:10.1016/j.amjmed.2017.02.010.

    PMID: 28285069
  6. 6

    Heart failure with reduced ejection fraction.

    Cannata A, Crespo-Leiro MG, Bromage DI, et al.

    Lancet (London, England) 2026; (407(10527)):529-542 doi:10.1016/S0140-6736(25)01851-3.

    PMID: 41319669
  7. 7

    European Journal of Heart Failure International Expert Position Paper-Utilization, optimization, and clinical benefits of steroidal mineralocorticoid receptor antagonists in heart failure with a reduced ejection fraction.

    Böhm M, Abdullakutty J, Bauersachs J, et al.

    European journal of heart failure 2026; (28(3)):513-534 doi:10.1093/ejhf/xuag106.

    PMID: 41955577
  8. 8

    True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis.

    Vukadinović D, Lavall D, Vukadinović AN, et al.

    American heart journal 2017; (188()):99-108 doi:10.1016/j.ahj.2017.03.011.

    PMID: 28577687
  9. 9

    Consensus statement on the current pharmacological prevention and management of heart failure.

    Sindone AP, De Pasquale C, Amerena J, et al.

    The Medical journal of Australia 2022; (217(4)):212-217 doi:10.5694/mja2.51656.

    PMID: 35908234
  10. 10

    SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

    Zannad F, Ferreira JP, Pocock SJ, et al.

    Lancet (London, England) 2020; (396(10254)):819-829 doi:10.1016/S0140-6736(20)31824-9.

    PMID: 32877652
  11. 11

    Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.

    Vaduganathan M, Claggett BL, Jhund PS, et al.

    Lancet (London, England) 2020; (396(10244)):121-128 doi:10.1016/S0140-6736(20)30748-0.

    PMID: 32446323
  12. 12

    Foundational drugs for HFrEF: the growing evidence for a rapid sequencing strategy.

    Docherty KF, McMurray JJV

    The British journal of cardiology 2022; (29(1)):2 doi:10.5837/bjc.2022.002.

    PMID: 35747316
  13. 13

    Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper.

    Silva-Cardoso J, Fonseca C, Franco F, et al.

    Revista portuguesa de cardiologia 2021; doi:10.1016/j.repc.2021.07.009.

    PMID: 34462172
  14. 14

    Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?

    Hu JR, Schwann AN, Tan JW, et al.

    Cardiology clinics 2023; (41(4)):511-524 doi:10.1016/j.ccl.2023.06.007.

    PMID: 37743074
  15. 15

    Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.

    Mullens W, Martens P, Testani JM, et al.

    European journal of heart failure 2022; (24(4)):603-619 doi:10.1002/ejhf.2471.

    PMID: 35239201
  16. 16

    Full decongestion in acute heart failure therapy.

    Buttar C, Alai H, Matanes FN, et al.

    The American journal of the medical sciences 2024; (368(3)):182-189 doi:10.1016/j.amjms.2024.06.002.

    PMID: 38880301
  17. 17

    What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?

    Khan MS, Vaduganathan M

    Current diabetes reports 2020; (20(11)):63 doi:10.1007/s11892-020-01347-3.

    PMID: 33040170
  18. 18

    Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.

    Greene SJ, Butler J, Albert NM, et al.

    Journal of the American College of Cardiology 2018; (72(4)):351-366 doi:10.1016/j.jacc.2018.04.070.

    PMID: 30025570
  19. 19

    [Heart failure in old age : Current recommendations in view of the revised national treatment guidelines on chronic heart failure].

    Lambrecht A, Hardt R

    Zeitschrift fur Gerontologie und Geriatrie 2019; (52(7)):701-712 doi:10.1007/s00391-019-01617-0.

    PMID: 31578609
  20. 20

    Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.

    Beldhuis IE, Lam CSP, Testani JM, et al.

    Circulation 2022; (145(9)):693-712 doi:10.1161/CIRCULATIONAHA.121.052792.

    PMID: 35226558
  21. 21

    Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.

    Damman K, Gori M, Claggett B, et al.

    JACC. Heart failure 2018; (6(6)):489-498 doi:10.1016/j.jchf.2018.02.004.

    PMID: 29655829
  22. 22

    Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.

    Butler J, Anker SD, Lund LH, et al.

    European heart journal 2022; (43(41)):4362-4373 doi:10.1093/eurheartj/ehac401.

    PMID: 35900838

This page is for informational purposes only and does not constitute medical advice. Your heart-failure care team should decide whether these medicines and monitoring plans are right for you; do not start, stop, or change medicines without their guidance.

Get notified when new evidence is published on systolic heart failure.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.